about
Differential protein stability and ALK inhibitor sensitivity of EML4-ALK fusion variants.Tumor VEGF:VEGFR2 autocrine feed-forward loop triggers angiogenesis in lung cancer.Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.Implementing amplicon-based next generation sequencing in the diagnosis of small cell lung carcinoma metastases.Notch signaling triggers the tumor heterogeneity of small cell lung cancer.Targeted expression of mutated ALK induces neuroblastoma in transgenic mice.Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung CancerSynergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancerPretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma
P50
Q27851880-D4D765F3-EBF8-49B4-A02E-5D11114C0987Q39186300-2E845F3C-A83E-46C2-89DC-AE2DCBE490E4Q39328851-D78A7F97-89AC-47CF-9DAC-2DB07C8489FDQ40346036-8CD214B8-F7D9-4E83-82D6-DEC975E774C7Q49393089-3EB59FA7-FE10-404D-A90C-81734B970043Q52301110-6C65DE3A-58AC-4979-B89E-FA0FA98E0F2EQ88732179-01E64AE7-463B-41AB-AE45-631058D592F3Q89412000-5648F1D0-9E16-48E6-B4EC-D5B41BF17F16Q90769136-E36A5434-D24E-4F97-99AB-5FBBEA6AF45A
P50
description
investigador
@es
researcher
@en
wetenschapper
@nl
name
Lydia Meder
@en
Lydia Meder
@nl
type
label
Lydia Meder
@en
Lydia Meder
@nl
prefLabel
Lydia Meder
@en
Lydia Meder
@nl
P31
P496
0000-0002-9547-5812